Schroders $SDR vote clears £9.9B Nuveen sale with 99.9% support
Original: Results of Court Meeting and General Meeting View original →
Schroders $SDR shareholders cleared a key step in Nuveen's £9.9B acquisition, with 99.92% of Scheme Shares voted for the Court Meeting resolution and 99.93% support for the Special Resolution at the General Meeting. The vote confirms shareholder approval for one of the largest asset-management M&A deals in Europe and keeps the transaction on track for an expected Q4 2026 completion.
The primary source is Schroders' RNS on the Court Meeting and General Meeting results. The acquisition is structured as a scheme of arrangement under Part 26 of the Companies Act 2006. Bidco is Pantheon, LLC, a newly incorporated subsidiary of Nuveen, LLC, which is part of TIAA.
| Vote | For | Against | Turnout reference |
|---|---|---|---|
| Court Meeting | 1,139,864,822 shares, 99.92% | 951,715 shares, 0.08% | 71.03% of eligible Scheme Shares |
| General Meeting item (a) | 1,138,317,958 votes, 99.93% | 813,772 votes, 0.07% | 1,139,131,730 total votes |
| General Meeting item (b) | 1,138,338,368 votes, 99.93% | 788,659 votes, 0.07% | 1,139,127,027 total votes |
The vote satisfies Conditions 2(A) and 2(B) in the scheme document, but the transaction is not complete. Schroders said the scheme remains subject to remaining conditions, including court sanction and delivery of the court order to the Registrar of Companies. Before the scheme becomes effective, applications will be made for Schroders shares to cease trading on the London Stock Exchange Main Market and for the Official List listing to be cancelled.
The broader market stake is consolidation in active asset management, where scale, distribution, and private-markets capabilities are increasingly central to margins. The next milestones are the court sanction hearing, regulatory clearances, any timetable update through the London Stock Exchange regulatory information service, and confirmation of the effective date that would trigger the listing cancellation.
Not investment advice. Verify all figures with primary sources before acting.
Related Articles
Eli Lilly agreed to acquire AtaiBeckley for $6.75 a share in cash, valuing the upfront consideration at about $2.8B. A CVR could add up to $2.50 a share, or about $1.0B, tied to BPL-003 and VLS-01 milestones.
Intertek $ITRK rose 12.6% in London after confirming it rejected EQT's indicative £51.50-a-share cash proposal. The UK testing group said the offer fundamentally undervalued the company, while EQT faces a May 14 UK takeover deadline.
ConocoPhillips $COP agreed to acquire a 42% interest in BP Energy Company of Kirkuk Limited, joining four producing fields in northern Iraq. The company release says the redevelopment covers more than 3B boe of initial recoverable resources and is expected to close by end-2026.